Text Size

High Dose Chemotherapy Followed By PBSC Rescue for HD

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186251
First received: September 13, 2005
Last updated: November 9, 2012
Last verified: July 2012
History of Changes
  Purpose

To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.


Condition Intervention
Hodgkin Disease
 Procedure: high dose chemo then auto hematopoietic cell transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

Resource links provided by NLM:

MedlinePlus related topics: Hodgkin Disease
U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Overall survival
  • FFS
  • Response rates

Secondary Outcome Measures:
  • Toxicity of high dose chemotherapy

Estimated Enrollment: 200
Study Start Date: March 1998
Estimated Study Completion Date: July 2005
Detailed Description:

Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease

  Eligibility

Ages Eligible for Study:   up to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:- adequate organ function

  • recurrent HD Exclusion Criteria:- CNS disease
  • no prior malignancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00186251

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Sally Arai Stanford University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00186251     History of Changes
Other Study ID Numbers: BMT24, BMT24, 13322
Study First Received: September 13, 2005
Last Updated: November 9, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
 Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on May 16, 2013